Medical Research Institute of New Zealand (Medical Research Institute of New Zealand)

概览

关联

93

项与 Medical Research Institute of New Zealand 相关的临床试验

Addressing gaps in the surveillance and response to influenza-like illness: A community pharmacy-based feasibility study,

开始日期2024-05-10

申办/合作机构

Medical Research Institute of New Zealand

ACTRN12624000294550 / Not yet recruiting临床3期

Randomized Controlled Trial of COVID-19 booster vaccine for intramuscular versus subcutaneous administration assessing immunogenicity and reactogenicity. in pharmacies/vaccination sites in Aotearoa, New Zealand.

开始日期2024-03-30

申办/合作机构

Medical Research Institute of New Zealand

ACTRN12623000958684 / Recruiting临床2期

The Prophylaxis against Early Ventilator Associated Lower Respiratory Tract Infection (PREVENT LRTI) trial. A phase 2 multi-centre, randomized, double-blind, placebo-controlled parallel group clinical trial.

开始日期2024-02-09

申办/合作机构

Medical Research Institute of New Zealand

100 项与 Medical Research Institute of New Zealand 相关的临床结果

登录后查看更多信息

0 项与 Medical Research Institute of New Zealand 相关的专利（医药）

登录后查看更多信息

546

项与 Medical Research Institute of New Zealand 相关的文献（医药）

2024-10-01·Intensive Care Medicine

Less is best for oxygen therapy in adults in the intensive care unit with severe hypoxaemia due to COVID-19

Letter

作者: Young, Paul J

2024-10-01·eClinicalMedicine

Time for the lens to focus on diagnostic algorithms in asthma

Article

作者: Beasley, Richard ; Noble, Jonathan

2024-09-15·American Journal of Respiratory and Critical Care Medicine

Impact of High-Dose Early Mobilization on Outcomes for Patients with Diabetes: A Secondary Analysis of the TEAM Trial

Article

作者: Bailey, Michael ; Brickell, Kathy ; Sivasuthan, Janani ; Tipping, Claire J. ; Gould, Doug W. ; Higgins, Alisa M. ; Zoungas, Sophia ; Harrold, Meg ; Young, Paul J. ; Broadley, Tessa ; Buhr, Heidi ; Presneill, Jeffrey J. ; Poole, Alex ; Nichol, Alistair D. ; Webb, Steven ; Iwashyna, Theodore J. ; Bellomo, Rinaldo ; Hurford, Sally ; Schaller, Stefan J. ; Serpa Neto, Ary ; Agli, Alicia ; Bradley, Scott ; Parke, Rachael ; Hodgson, Carol L. ; Gabbe, Belinda J. ; Seller, Daniel

Rationale: Patients with diabetes represent almost 20% of all ICU admissions and might respond differently to high-dose early active mobilization. Objectives: To assess whether diabetes modified the relationship between the dose of early mobilization on clinical outcomes in the TEAM trial. Methods: All TEAM trial patients were included. The primary outcome was days alive and out of the hospital at Day 180. Secondary outcomes included 180-day mortality and long-term functional outcomes at Day 180. Logistic and median regression models were used to explore the effect of high-dose early mobilization on outcomes by diabetes status. Measurements and Main Results: All 741 patients from the original trial were included. Of these, 159 patients (21.4%) had diabetes. Patients with diabetes had fewer days alive and out of the hospital at Day 180 (124 [0-153] vs. 147 [82-164]; P = 0.013) and higher 180-day mortality (30% vs. 18%; P = 0.044). In patients receiving high-dose early mobilization, the number of days alive and out of the hospital at Day 180 was 73.0 (0.0-144.5) in patients with diabetes and 146.5 (95.8-163.0) in patients without diabetes (P value for interaction = 0.108). However, in patients with diabetes, high-dose early mobilization increased the odds of mortality at 180 days (adjusted odds ratio, 3.47; 95% confidence interval, 1.67-7.61; P value for interaction = 0.001). Conclusions: In this secondary analysis of the TEAM trial, in patients with diabetes, a high-dose early mobilization strategy did not significantly decrease the number of days alive and out of the hospital at Day 180, but it increased 180-day mortality.

100 项与 Medical Research Institute of New Zealand 相关的药物交易

登录后查看更多信息

100 项与 Medical Research Institute of New Zealand 相关的转化医学

登录后查看更多信息